Recurrent ovarian cancer: Use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival

Radiology

Volumn 257, Issue 1, 2010, Pages 125-134

  Sala, Evis ^a   Kataoka, Masako ^a   Pandit Taskar, Neeta ^b   Ishill, Nicole ^b   Mironov, Svetlana ^b   Moskowitz, Chaya S ^b   Mironov, Oleg ^b   Collins, Michelle A ^b   Chi, Dennis S ^b   Larson, Steven ^b   Hricak, Hedvig ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; OVARY CARCINOMA; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER;

AREA UNDER CURVE; CONTRAST MEDIA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBSERVER VARIATION; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77957336103     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10092279     Document Type: Article

References (31)

1. American Cancer Society. Cancer facts & figures 2009. Atlanta, Ga: American Cancer Society, 2009.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249.
3. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9(7):1138-1150.
4. Rose PG. Surgery for recurrent ovarian cancer. Semin Oncol 2000;27(3 suppl 7):17-23.
5. Folk JJ, Botsford M, Musa AG. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure. Gynecol Oncol 1995;57(2):178-182.
6. Patsner B, Orr JW Jr, Mann WJ Jr, Taylor PT, Partridge E, Allmen T. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease? Gynecol Oncol 1990;38(3):373-376.
7. Rubin SC, Hoskins WJ, Hakes TB, et al. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 1989;160(3):667-671.
8. Forstner R, Hricak H, Powell CB, Azizi L, Frankel SB, Stern JL. Ovarian cancer recurrence: value of MR imaging. Radiology 1995;196(3):715-720.
9. Kubik-Huch RA, Dörffler W, von Schulthess GK, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10(5):761-767. (Pubitemid 30321087)
10. Kurtz AB, Tsimikas JV, Tempany CM, et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis - report of the Radiology Diagnostic Oncology Group. Radiology 1999;212(1):19-27.
11. Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities - report from the Radiological Diagnostic Oncology Group. Radiology 2000;215(3):761-767.
12. Coakley FV, Choi PH, Gougoutas CA, et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 2002;223(2):495-499. (Pubitemid 34454332)
13. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 2009;71(1):164-174.
14. Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging 2008;35(8):1439-1448.
15. Nanni C, Rubello D, Farsad M, et al. (18) F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 2005;31(7):792-797. (Pubitemid 41194659)
16. Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology 2004;233(2):433-440. (Pubitemid 39423802)
17. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007;105(1):17-22. (Pubitemid 46441448)
18. Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol 2009;112(3):462-468.
19. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006;103(1):271-276. (Pubitemid 44374699)
20. Soussan M, Wartski M, Cherel P, et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 2008;108(1):160-165.
21. Vinnicombe SJ, Norman AR, Nicolson V, Husband JE. Normal pelvic lymph nodes: evaluation with CT after bipedal lymphangiography. Radiology 1995;194(2):349-355.
22. Obuchowski NA. Nonparametric analysis of clustered ROC curve data. Biometrics 1997;53(2):567-578.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
24. Zhou XH, Obuchowski NA, McClish DK. Statistical methods in diagnostic medicine. New York, NY: Wiley-Interscience, 2002.
25. Bristow RE, Giuntoli RL 2nd, Pannu HK, Schulick RD, Fishman EK, Wahl RL. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005;99(2):294-300.
26. Chung HH, Kang WJ, Kim JW, et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007;34(4):480-486.
27. Hauth EA, Antoch G, Stattaus J, et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 2005;56(2):263-268.
28. Mangili G, Picchio M, Sironi S, et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 2007;34(5):658-666. (Pubitemid 46669366)
29. Pannu HK, Bristow RE, Cohade C, Fishman EK, Wahl RL. PET-CT in recurrent ovarian cancer: initial observations. RadioGraphics 2004;24(1):209-223. (Pubitemid 38134606)
30. Sebastian S, Lee SI, Horowitz NS, et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging 2008;33(1):112-118.
31. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106(9):1933-1939. (Pubitemid 43673208)